Physician profile
Marcel M Benoit
NPI 1609855725
$796.56
in general payments reported to CMS, 2019-2025
13 companies · $146 in 2025
The $146 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $413 · 2020: $83.97 · 2021: $36.27 · 2022: $98.02 · 2023: $19.62 · 2025: $146.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $146 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $146.01 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $124.82 | 2025 | Voquezna |
| Abbvie INC. | $124.43 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $118.39 | 2019 | |
| Ivantis, INC | $105.26 | 2019 | |
| Alkermes, INC. | $98.02 | 2022 | |
| Global Blood Therapeutics, INC. | $83.97 | 2020 | |
| Lilly USA, LLC | $29.48 | 2019-2021 | |
| Eisai INC. | $21.49 | 2021 | |
| Pfizer INC. | $21.19 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.62 | 2023 | |
| Nalpropion Pharmaceuticals LLC | $19.38 | 2019 | |
| Avanir Pharmaceuticals, INC. | $17.46 | 2019 | |
| Currax Pharmaceuticals LLC | $13.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marcel Benoit listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.